Last week I had one of my final presentations of the year! With a catchy title😉
Urine for an Update! Updates in the management of metastatic urothelial cancer
Hold your bladders, this is an extensive update! 😂 #oncopharm
Bladder cancer can be divided into two ✌️subtypes: 1) Non-muscle invasive: encompasses in-situ and localized disease➡️5-yr OS >70%
2) Muscle invasive: encompasses regional or metastatic disease➡️5-yr OS dismal especially for metastatic disease 😔
Cisplatin=SOC
50% of pts w are ineligible due to older age👵🏻, poor PS, ⬇️ renal function, ⬇️hearing, neuropathy, heart failure 🫀& other comorbities that ⬆️ risk of ⚠️
Carboplatin yields inferior responses➡️NOT 🙅🏻♀️ an equal alternative due to ⬇️ OS😢➡️pt left w/minimal tx options
What medications 💊 are should be avoided 🛑 or used with caution ⚠️ in patients with Myasthenia Gravis? 🤔
See 👀 the thread 🧵below⤵️ that summarizes an amazing grand rounds presentation by @UKPharmRes PGY1 @AliW_PharmD on key 🔑 medication considerations in MG
1️⃣Antibiotics to avoid or use w/caution🦠 💊
🛑FQs = FDA BBW for ⤴️ risk of MG crisis ➡️ avoid use if possible
⚠️ Macrolides ⤴️ rate of MG crisis (case reports)
⚠️ AG linked to ⤴️ ICU acquired weakness & exacerbate ‼️ MG crisis
📝Risk⬆️ w/neomycin vs. tobramycin & amikacin
Antibiotics considered to be SAFE alternatives to the above include
✅Beta-lactams
✅Tetracyclines
✅Linezolid
✅Bactrim
Ex. In an MG patient who presents 🏥 w/CAP 🫁 ➡️ choose ceftriaxone + doxycycline✅ OVER ceftriaxone + azithromycin🛑